## Disease Modeling and Drug Discovery with Human Pluripotent Stem Cells

## Shiang Lim (Max)

### **Cardiac Regeneration Group**







#### 13<sup>th</sup> December 2019

Disease Modeling and Drug Discovery with Human Pluripotent Stem Cell derived vascularized and innervated cardiac organoids

## Shiang Lim (Max)

## **Cardiac Regeneration Group**







#### 13<sup>th</sup> December 2019

## Cardiovascular disease – a leading cause of death



- 17.9 million per year around the would
- 31% of all global death worldwide



20% of Australians suffer from cardiovascular disease



1.1 million hospitalization in 2015-16, 11% of all hospitalization



\$8.8 billion annually in Australia

\$351.2 billion annually in USA

## An unmet medical need – Why?

#### **Current treatment options**

- Not always compatible with pre-existing conditions & medications
- Undesirable side effects

#### Current heart disease models

- Not clinically relevant
- Too simple



#### Drug efficacy and toxicity is often human-specific

### The human heart is complex





Cardiac vascular system



Autonomic nervous system





#### An unmet medical need – Solution?

## We need better drug screening model to find better medications

To develop a multicellular cardiac organoid model to faithfully recapitulate heart physiology for predictive drug testing and for novel target identification

## Engineered human 3D heart organoid with integrated blood vessels and a nervous system



Induced pluripotent stem cells (iPSCs)

- Carry an individual's genetic make-up
- Unlimited source of cells
- Transform into all cell types in the body

## Engineered human 3D heart organoid with integrated blood vessels and a nervous system



## Cardiomyocytes derived from human iPSCs



Lim et al. (2013) Stem Cells Transl Med; 3:787 Hoque et al. (2018) Cell Death Disc; 4:39

#### **Endothelial cells derived from human iPSCs**



Kong et al. (2019) Acta Biomater, 94:281-294

#### Sympathetic neurons derived from human iPSCs



# Engineered human 3D heart organoid with integrated blood vessels and a nervous system



## Electrophysiology and contractility of cardiac organoids









Beat rate = **168.5 ± 7 bpm** (n=14)

### Single cell RNA-seq of cardiac organoids



## Cardiac organoids are scalable with optimal diffusion



Qtracker = 20 nm in diameter

## Cardiac organoids contain interconnected vessellike structure with lumens



### Cardiac organoids are vascularised and innervated



CD31+ endothelial cells

**PRPH+** sympathetic neurons

### Cardiac organoids can model cardiac injury



Simulated ischaemia = 2 hours Simulated reperfusion = 24 hour

## Summary





#### 3D beating heart organoids

- Human-specific
- Vascularised and innerverated
- Reproducible
- Scalable for high-throughput drug screening
- Model cardiac injury
- Future clinical trial in a dish

#### **Acknowledgement**

#### St Vincent's Institute

Cardiac Regeneration (OBI) Jarmon Lees Priya Sivakumaran Anne Kong

Vascular Biology (OBI) Geraldine Mitchell

Bioinformatics & Cellular Genomics Davis McCarthy Ruqian Lyu

#### University of Wollongong Mirella Dottori

#### **University of Melbourne**

Alice Pébay Damián Hernández Andrew Allen Jaspreet Bassi

#### **Swinburne University**

Gavin Lambert Nina Eikelis

#### <u>WEHI</u>

Edwin Hawkins Joy Liu Stephen Wilcox Casey Anttila

#### **Funding**

Stafford Fox Medical Research NHMRC St Vincent's REF CASS Foundation National Ataxia Foundation

